摘要
化疗是进展期胃癌的主要治疗方法,主要是细胞毒性药物联合用药方案杀伤肿瘤细胞,因化疗药物特异性差,其在杀伤肿瘤细胞的基础上也对正常细胞产生损害,所以传统的化疗药物存在明确的副作用。本文综述了胃癌靶向治疗最新研究进展,其中胃癌相关因素介绍了表皮生长因子受体(EGFR)、人类表皮生长因子受体2(HER2)、血管内皮生长因子(VEGF)、PI3K/m TOR、C-Met、聚腺苷二磷酸-核糖聚合酶(PARP)、纤维母细胞生长因子受体(FGFR)、FGFR-1等,针对这几方面临床上已经开发了许多分子靶向药物如:西妥昔单抗、曲妥珠单抗、拉帕替尼、帕妥珠单抗、贝伐单抗、雷帕霉素、西罗莫司、依维莫司、MK-866、Rilotumumab、Olaparib等,以及2014年ASCO公布的两项Ⅲ期临床试验结果并分别于国内及美国上市的阿帕替尼及Ramucirumab,这些靶向药物针对肿瘤特定的标志物发挥作用,具有特异性强、副作用小的优点,在药效上取得了很好的成果,并为患者抗肿瘤"个体化治疗"提供了新的治疗方案。
Chemotherapy is mainly used in the treatment for advanced gastric cancer. However, therapy of cytotoxic drug combination has poor speci- ficity in killing tumor cells and normal cells, so there are clear side effects in traditional chemothera- py. This paper reviews gastric cancer related factors and the advances of target therapy for gastric cancer factors, include EGFR, HER2, VEGF, PI3K/ mTOR, C-Met, PARP, FGFR, FGFR-1 and so on. Researchers have developed many molecular targeted drugs in clinic ： Cetuximab, Apatinib, Ramucirumab, trastuzumab, lapatinib, pertuzumab, bevacizumab,rapamycin, sirolimus, everolimus, MK-866, Rilotu- mumab, Olapar/b and so on. These targeted drugs play a role against tumor-specific markers with the advantage of specificity and fewer side effects. In view of good efficacy, these drugs will provide a new treatment program for patients with anti-tumor ＂indi- vidual treatment＂.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2015年第8期950-955,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
